Transport of HIV-protease inhibitors across 1α,25di-hydroxy vitamin d3-treated calu-3 cell monolayers: Modulation of p-glycoprotein activity

Pharmaceutical Research

Volumn 19, Issue 11, 2002, Pages 1696-1703

  Patel, Jignesh ^a   Pal, Dhananjay ^a   Vangala, Veena ^a   Gandhi, Mohit ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Anti HIV agents; Calu 3; Efflux; Induction; P glycoprotein; Permeability

Indexed keywords

CALCITRIOL; CYCLOSPORIN; CYCLOSPORIN A; GLYCOPROTEIN P; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TESTOSTERONE; TRITIUM; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL MEMBRANE TRANSPORT; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG TRANSPORT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BILAYER; LUNG ALVEOLUS CELL; MUCUS SECRETION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY EPITHELIUM; WESTERN BLOTTING;

BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; HIV PROTEASE INHIBITORS; HUMANS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 0036844744     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020761514471     Document Type: Article

References (30)

1. R. B. Kim, M. F. Fromm, C. Wandel, B. Leake, A. J. Wood, D.M. Roden and G. R. Wilkinson. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294 (1998).
2. E. F. Choo, B. Leake, C. Wandel, H. Imamura, A. J. Wood, G. R. Wilkinson and R. B. Kim. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug. Metab. Dispos. 28:655-660 (2000).
3. S. M. Hammer, K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakeweitz and M. A. Fischel. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. 337:725-733 (1997).
4. G. H. Friedland, R. Pollard, B. Griffith, M. Hughes, G. Morse, R. Bassett, W. Freimuth, L. Demeter, E. Connick, T. Nevin, M. Hirsch and M. Fischl. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 team. J. Acquir. Immune Defic. Syndr. 21:281-292 (1999).
5. P. Langmann, M. Zilly, B. Weissbrich, C. Schlor, T. Vath, E. Richter and H. Klinker. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir. Eur. J. Med. Res. 5:59-62 (2000).
6. N. C. White, C. Agostini, D. Israel-Biet, G. Semenzato, and J. R. Clarke. The growth and the control of human immunodeficiency virus in the lung: Implications for highly active antiretroviral therapy. Eur. J. Clin. Invest. 29:964-972 (1999).
7. S. Taylor, D. J. Back, S. M. Drake, J. Workman, H. Reynolds, S. E. Gibbons, D. J. White and D. Pillay. Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir. J. Antimicrob. Chemother. 49:227 (2002).
8. S. Taylor, D. J. Back, S. M. Drake, J. Workman, H. Reynolds, S. E. Gibbons, D. J. White and D. Pillay. Antiretroviral drug concentrations in semen of HIV-infected men: Differential penetration of indinavir, ritonavir and saquinavir. J. Antimicrob. Chemother. 48:351-354 (2001).
9. S. M. Crowe and S. Sonza. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: A further obstacle to eradication. J. Leukoc. Biol. 68:345-350 (2000).
10. R. M. Hoetelmans. Sanctuary sites in HIV-1 infection. Antivir. Ther. 3:13-17 (1998).
11. T. Bagrij, S. B. Hladky, S. Stewart, R. J. Scheper, and M. A. Barrand. Studies of multidrug transport proteins in cells derived from human lung samples. Int. J. Clin. Pharmacol. Ther. 36:80-81 (1998).
12. C. M. Waters, T. C. Krejcie, and M. J. Avram. Facilitated uptake of fentanyl, but not alfentanil, by human pulmonary endothelial cells. Anesthesiology 93:825-831 (2000).
13. P. C. Hopewell and J. M. Luce. Pulmonary involvement in the acquired immunodeficiency syndrome. Chest 87:104-112 (1985).
14. J. R. Clarke, A. J. Gates, R. J. Coker, J. A. Douglass, J. D. Williamson, and D. M. Mitchell. HIV-1 proviral DNA copy number in peripheral blood leucocytes and bronchoalveolar lavage cells of AIDS patients. Clin. Exp. Immunol. 96:182-186 (1994).
15. R. M. Rose, A. Krivine, P. Pinkston, J. M. Gillis, A. Huang, and S. M. Hammer. Frequent identification of HIV-1 DNA in bronchoalveolar lavage cells obtained from individuals with the acquired immunodeficiency syndrome. Am. Rev. Respir. Dis. 143:850-854 (1991).
16. M. Demeule, M. Labelle, A. Regina, F. Berthelet, and R. Beliveau. Isolation of endothelial cells from brain, lung, and kidney: Expression of the multidrug resistance P-glycoprotein isoforms. Biochem. Biophys. Res. Commun. 281:827-834 (2001).
17. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270:414-423 (1994).
18. J. C. Kolars, P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 90:1871-1878 (1992).
19. G. D. Kanmogne, R. C. Kennedy, and P. Grammas. Analysis of human lung endothelial cells for susceptibility to HIV type 1 infection, coreceptor expression, and cytotoxicity of gp120 protein. AIDS Res. Hum. Retroviruses. 17:45-53 (2001).
20. H. L. Winton, H. Wan, M. B. Cannell, D.C. Gruenert, P. J. Thompson, D. R. Garrod, G. A. Stewart and C. Robinson. Cell lines of pulmonary and non-pulmonary origin as tools to study the effects of house dust mite proteinases on the regulation of epithelial permeability. Clin. Exp. Allergy. 28:1273-1285 (1998).
21. K. O. Hamilton, M. A. Yazdanian, and K. L. Audus. Modulation of P-glycoprotein activity in Calu-3 cells using steroids and beta-ligands. Int. J. Pharm. 228:171-179 (2001).
22. K. O. Hamilton, E. Topp, I. Makagiansar, T. Siahaan, M. Yazdanian, and K. L. Audus. Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J. Pharmacol. Exp. Ther. 298:1199-1205 (2001).
23. K. O. Hamilton, G. Backstrom, M A. Yazdanian, and K. L. Audus. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J. Pharm. Sci. 90:647-658 (2001).
24. K. A. Foster, M. L. Avery, M. Yazdanian, and K. L. Audus. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 208:1-11 (2000).
25. P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins, Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxy-vitamin D3. Mol. Pharmacol. 51:741-754 (1997).
26. I. Pezron, R. Mitra, D. Pal, and A. K. Mitra. Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3). J. Pharm. Sci. 91:1135-1146 (2002).
27. C. D. Tran, P. Timmins, B. R. Conway, and W. J. Irwin. Investigation of the coordinated functional activities of cytochrome P450 3A4 and P-glycoprotein in limiting the absorption of xenobiotics in Caco-2 cells. J. Pharm. Sci. 91:117-128 (2002).
28. J. W. Polli, S. A. Wring, J. E. Humphreys, L. Huang, J. B. Morgan, L. O. Webster and C. S. Serabjit-Singh. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:620-628 (2001).
29. K. Kawazu, K. Yamada. M. Nakamura, and A. Ota. Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin. Invest. Ophthalmol. Vis. Sci. 40:1738-1744 (1999).
30. D. K. Yu. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 39:1203-1211 (1999).